Disodium Phosphocreatine Cyclodextrin Inclusion Complex

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing creatine formulations face challenges with stability and bioavailability due to degradation in the acidic stomach environment and suboptimal transport across intestinal mucosal cells.

Innovation Solution

A formulation combining disodium phosphocreatine with cyclodextrin, co-granulated and coated with methacrylate copolymers, which protects creatine from gastric degradation and enhances intestinal uptake.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If creatine monohydrate is ingested orally, then it can be taken up by skeletal muscle to enhance performance, but it degrades rapidly in the stomach to form creatinine and is not fully solubilized in cold or room temperature water

Engineering Contradiction:
Improvestability of creatine in gastric environmentVSAvoiddegradation to creatinine
Core Design Contradiction:
ReliabilityVSLoss of substance

Solution Approach 1:

Cyclodextrin serves as an intermediary host molecule that forms an inclusion complex with creatine. The cyclodextrin cavity encapsulates the creatine molecule, protecting it from degradation by gastric juices while maintaining solubility in cold or room temperature water. This host-guest complex prevents the harmful conversion of creatine to creatinine during gastric passage.

Inventive Principle:
Principle #24Intermediary (Mediator)

Solution Approach 2:

The invention creates a composite formulation combining creatine with cyclodextrin in a specific molar ratio (1:1 to 1:10). This composite material exhibits properties that neither component possesses alone: the cyclodextrin provides protection and solubility enhancement, while the creatine maintains its bioactive function. The composite structure stabilizes creatine against degradation while improving its physical properties.

Inventive Principle:
Principle #40Composite materials

2Reliability

If creatine is protected from degradation in the stomach, then stability is improved, but transport across intestinal mucosal cells remains suboptimal

Engineering Contradiction:
Improveprotection from gastric degradationVSAvoidtransport across intestinal mucosa
Core Design Contradiction:
ReliabilityVSEase of operation

Solution Approach 1:

The cyclodextrin inclusion complex changes the physical-chemical parameters of creatine, including its size, shape, and surface properties. This parameter modification enables the creatine-cyclodextrin complex to interact more effectively with intestinal mucosal cells, facilitating improved transport and absorption while maintaining protection from gastric degradation.

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The formulation significantly improves creatine bioavailability by protecting it from stomach acid and facilitating controlled release and absorption in the intestines, leading to enhanced muscle energy supply and potential benefits for muscle-wasting disorders.

Implementation Method 1

cyclodextrin...protects the creatine as it comes in contact with gastric juices

Methodology Applied
Scientific EffectInclusion complex formation: Solvation

Implementation Method 2

coated with methacrylate copolymers, which protects creatine from gastric degradation and enhances intestinal uptake

Methodology Applied
Scientific EffectControlled release:

Data Source

PatentUS12280067B2Formulations of creatine and cyclodextrin exhibiting improved bioavailability
Publication Date: 2025.04.22 PHENOLICS LLC
  • US12280067B2 patent drawing
  • US12280067B2 patent drawing
  • US12280067B2 patent drawing

AI summary

Formulations of creatine, preferably phosphocreatine and most preferably disodium phosphocreatine, combined with cyclodextrin exhibit improved uptake across digestive mucosa, including intestinal, esophageal, and stomach mucosa. In particular, the formulations of the present invention are designed for protection of the cyclodextrin as it comes in contact with gastric juices so as to allow thereafter for unexpectedly improved site-specific intestinal release.